Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M. Kuriwaki I, et al. Among authors: hirano m. Bioorg Med Chem. 2020 May 15;28(10):115453. doi: 10.1016/j.bmc.2020.115453. Epub 2020 Mar 28. Bioorg Med Chem. 2020. PMID: 32278710
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Kondoh Y, Terasaka T, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Nakazawa T, Hirano M. Kuriwaki I, et al. Among authors: hirano m. Bioorg Med Chem. 2021 Mar 1;33:116019. doi: 10.1016/j.bmc.2021.116019. Epub 2021 Jan 16. Bioorg Med Chem. 2021. PMID: 33486159
Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Terasaka T, Iwai Y, Noda A, Tomiyama H, Kikuchi A, Hirano M. Kuriwaki I, et al. Among authors: hirano m. Bioorg Med Chem. 2022 Apr 1;59:116657. doi: 10.1016/j.bmc.2022.116657. Epub 2022 Feb 11. Bioorg Med Chem. 2022. PMID: 35219181
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S. Tanaka H, et al. Among authors: hirano m. Mol Cancer Ther. 2019 Aug;18(8):1366-1373. doi: 10.1158/1535-7163.MCT-18-0976. Epub 2019 May 15. Mol Cancer Ther. 2019. PMID: 31092564
Effects of different educational interventions on cervical cancer knowledge and human papillomavirus vaccination uptake among young women in Japan: Preliminary results of a cluster randomized controlled trial.
Takahashi Y, Sasamori Y, Higuchi R, Kaku A, Kumagai T, Watanabe S, Nishizawa M, Takasaki K, Nishida H, Ichinose T, Hirano M, Miyagawa Y, Hiraike H, Kido K, Ishikawa H, Nagasaka K. Takahashi Y, et al. Among authors: hirano m. PLoS One. 2025 Jan 7;20(1):e0311588. doi: 10.1371/journal.pone.0311588. eCollection 2025. PLoS One. 2025. PMID: 39774513 Clinical Trial.
L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Ishihara T, Tada M, Kanemitsu Y, Takahashi Y, Ishikawa K, Ikenaka K, Hirano M, Yokota T, Minakawa EN, Saito K, Nagai Y, Onodera O. Ishihara T, et al. Among authors: hirano m. EClinicalMedicine. 2024 Nov 25;78:102952. doi: 10.1016/j.eclinm.2024.102952. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39764542 Free PMC article.
2,308 results